{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T13:30:38Z","timestamp":1777555838328,"version":"3.51.4"},"reference-count":25,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2016,9,25]],"date-time":"2016-09-25T00:00:00Z","timestamp":1474761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Diabetes Sci Technol"],"published-print":{"date-parts":[[2017,3]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>\n                      Insulin glargine 300 U\/mL (Gla-300) contains the same active ingredient as glargine 100 U\/mL (Gla-100), and provides the same number of units in one-third of the volume. The SoloSTAR\n                      <jats:sup>\u00ae<\/jats:sup>\n                      injector pen has been modified to ensure accurate administration of this reduced volume and to improve user experience.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Insulin- and pen-na\u00efve adults with type 2 diabetes (T2DM) inadequately controlled with oral antihyperglycemic drugs, who had glycated hemoglobin (HbA1c) levels of 7.0-11.0 % (53-97 mmol\/mol) were studied. They received once-daily Gla-300 in this 4-week, multicenter, open-label, single-arm study (NCT02227212). Ease of use\/ease of learning (the primary endpoint), glycemic control, safety, and reliability of the disposable (prefilled) Gla-300 injector pen (secondary endpoints) were evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>At week 4, 95.0% of 40 participating subjects assessed the pen as excellent\/good and none as poor\/very poor; 97.5% would recommend it to others. Total Diabetes Treatment Satisfaction Questionnaire scores were stable throughout the study. Mean (SD) fasting plasma glucose levels decreased from 166.1 (35.0) mg\/dL at baseline to 124.2 (41.1) mg\/dL at week 4. No product technical complaints (PTCs) or adverse events (AEs) related to PTCs were reported. The number of subjects experiencing hypoglycemic events of any kind and the incidence of AEs were low. No serious AEs were reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>The Gla-300 injector pen is easy to use and easy to learn to use, with demonstrable reliability and high degrees of acceptance and treatment satisfaction. Once-daily Gla-300 basal insulin treatment was well tolerated and effective in pen- and insulin-na\u00efve adult T2DM subjects.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/1932296816668877","type":"journal-article","created":{"date-parts":[[2016,9,23]],"date-time":"2016-09-23T21:49:46Z","timestamp":1474667386000},"page":"263-269","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":7,"title":["Ease of Use of the Insulin Glargine 300 U\/mL Pen Injector in Insulin-Na\u00efve People With Type 2 Diabetes"],"prefix":"10.1177","volume":"11","author":[{"given":"Harald","family":"Pohlmeier","sequence":"first","affiliation":[{"name":"Center for Diabetes and Vascular Disease, Muenster, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lori","family":"Berard","sequence":"additional","affiliation":[{"name":"Winnipeg Regional Health Authority Health Sciences Centre, Winnipeg, MB, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire","family":"Brulle-Wohlhueter","sequence":"additional","affiliation":[{"name":"Sanofi, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junlong","family":"Wu","sequence":"additional","affiliation":[{"name":"Sanofi China, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raphael","family":"Dahmen","sequence":"additional","affiliation":[{"name":"Sanofi-Aventis Deutschland GmbH, Frankfurt am Main, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene","family":"Nowotny","sequence":"additional","affiliation":[{"name":"Sanofi-Aventis Deutschland GmbH, Frankfurt am Main, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Klonoff","sequence":"additional","affiliation":[{"name":"Diabetes Research Institute, Mills-Peninsula Health Services, San Mateo, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2016,9,25]]},"reference":[{"key":"bibr1-1932296816668877","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.26.11.3080"},{"key":"bibr2-1932296816668877","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1203858"},{"key":"bibr3-1932296816668877","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.28.2.254"},{"key":"bibr4-1932296816668877","unstructured":"Sanofi. Toujeo: highlights of prescribing information. Available at: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/206538s000lbl.pdf. Accessed May 20, 2015."},{"key":"bibr5-1932296816668877","unstructured":"Sanofi. Toujeo: summary of product characteristics. Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000309\/WC500047935.pdf. Accessed May 20, 2015."},{"key":"bibr6-1932296816668877","unstructured":"Health Canada. Toujeo: regulatory decision summary. Available at http:\/\/www.hc-sc.gc.ca\/dhp-mps\/prodpharma\/rds-sdr\/drug-med\/rds_sdr_toujeo_173316-eng.php. Accessed June 29, 2015."},{"key":"bibr7-1932296816668877","unstructured":"Australian Register of Therapeutic Goods. Toujeo: product information. Available at: https:\/\/www.tga.gov.au\/artg\/artg-id-223457. Accessed February 29, 2016."},{"key":"bibr8-1932296816668877","doi-asserted-by":"crossref","first-page":"637","DOI":"10.2337\/dc14-0006","volume":"38","author":"Becker RH","year":"2015","journal-title":"Diabetes Care"},{"key":"bibr9-1932296816668877","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12438"},{"key":"bibr10-1932296816668877","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-0991"},{"key":"bibr11-1932296816668877","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-0990"},{"key":"bibr12-1932296816668877","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12618"},{"key":"bibr13-1932296816668877","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12619"},{"key":"bibr14-1932296816668877","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-0249"},{"key":"bibr15-1932296816668877","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12283"},{"key":"bibr16-1932296816668877","doi-asserted-by":"publisher","DOI":"10.1177\/1932296815601441"},{"key":"bibr17-1932296816668877","doi-asserted-by":"publisher","DOI":"10.1177\/1932296815586219"},{"key":"bibr18-1932296816668877","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2012.0067"},{"key":"bibr19-1932296816668877","first-page":"111","volume-title":"Handbook of Psychology and Diabetes: A Guide to Psychological Measurement in Diabetes Research and Practice","author":"Bradley C","year":"1994"},{"key":"bibr20-1932296816668877","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.28.5.1245"},{"key":"bibr21-1932296816668877","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2012.03605.x"},{"key":"bibr22-1932296816668877","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.28.10.2543"},{"key":"bibr23-1932296816668877","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hcm031"},{"key":"bibr24-1932296816668877","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2014.12.016"},{"key":"bibr25-1932296816668877","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-015-0266-5"}],"container-title":["Journal of Diabetes Science and Technology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1932296816668877","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1932296816668877","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1932296816668877","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T18:12:14Z","timestamp":1777399934000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1932296816668877"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,25]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["10.1177\/1932296816668877"],"URL":"https:\/\/doi.org\/10.1177\/1932296816668877","relation":{},"ISSN":["1932-2968","1932-2968"],"issn-type":[{"value":"1932-2968","type":"print"},{"value":"1932-2968","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,25]]}}}